2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
47
Lung Neoplasms
28
Neoplasms
27
Colorectal Neoplasms
21
Prostatic Neoplasms
16
Hematologic Neoplasms
10
Uterine Cervical Neoplasms
9
Fatigue
9
Anxiety Disorders
8
Neoplasm Metastasis
7
Lymphoma
7
Hematopoietic and Lymphatic System Neoplasm
7
Papillomavirus Infections
6
Melanoma
6
Ovarian Neoplasms
5
Multiple Myeloma
5
Head and Neck Neoplasms
5
Gastrointestinal Neoplasms
5
Depression
5
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Skin Neoplasms
4
Obesity-Related Malignant Neoplasm
4
Obesity
4
Motor Activity
4
Hematopoietic and Lymphoid System Neoplasm
4
Breast Carcinoma In Situ
4
Triple Negative Breast Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Interventions
pembrolizumab
91
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
25
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Educational Status
×
Clear all
NCT05154084
2023-11-14
RESECT
British Urology Researchers in Surgical Training
Completed
19,505 enrolled